Vera Therapeutics, Inc. $VERA Shares Purchased by Candriam S.C.A.

Candriam S.C.A. raised its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 5.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 475,335 shares of the company’s stock after buying an additional 25,781 shares during the period. Candriam S.C.A.’s holdings in Vera Therapeutics were worth $19,123,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its stake in Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Vera Therapeutics in the fourth quarter valued at $46,000. Quantbot Technologies LP purchased a new position in shares of Vera Therapeutics in the second quarter valued at $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Vera Therapeutics during the 4th quarter worth $71,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Down 1.1%

Vera Therapeutics stock traded down $0.45 during trading on Friday, hitting $42.00. The company’s stock had a trading volume of 3,402,946 shares, compared to its average volume of 2,289,459. The stock’s fifty day moving average is $36.63 and its 200 day moving average is $41.10. Vera Therapeutics, Inc. has a 1-year low of $19.07 and a 1-year high of $56.05. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -7.58 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the firm posted ($0.81) earnings per share. As a group, equities research analysts predict that Vera Therapeutics, Inc. will post -6.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on VERA. Guggenheim increased their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. TD Cowen lifted their price objective on Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wedbush upped their target price on Vera Therapeutics from $35.00 to $43.00 and gave the company a “neutral” rating in a research note on Wednesday. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.58.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Recent coverage highlights continued bullish views on VERA after the FDA approval of its kidney disease treatment, with one article arguing the stock could still be well below fair value despite the big post-approval rally. Vera Therapeutics Could Be 92% Below Fair Value After FDA Approval
• Positive Sentiment: HC Wainwright and other analysts maintained buy ratings and, in some cases, raised price targets, signaling confidence in Vera’s launch opportunity and longer-term growth potential. HC Wainwright Gives Vera Therapeutics New $125 Price Target
• Positive Sentiment: The company announced inducement grants to eight new employees, which can be viewed as a routine hiring/retention step supporting commercialization efforts. Vera Therapeutics Announces Inducement Grants

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares of the company’s stock, valued at $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 106,201 shares of company stock worth $4,348,762 over the last ninety days. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.